Daniel A Pollyea Selected Research

Daniel A Pollyea Research Topics

Disease

69	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024 - 11/2010
20	Leukemia 01/2023 - 05/2013
12	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023 - 12/2017
11	Neoplasms (Cancer) 01/2023 - 03/2004
7	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 01/2017
5	Disease Progression 01/2023 - 04/2013
4	B-Cell Lymphoma (Lymphoma, B Cell) 10/2020 - 01/2018
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2023 - 09/2014
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023 - 09/2014
3	Thrombocytopenia (Thrombopenia) 01/2023 - 01/2015
3	Anemia 12/2022 - 01/2015
3	Cytopenia 01/2021 - 01/2015
2	Pneumonia (Pneumonitis) 12/2022 - 01/2019
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 09/2023
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2023
1	Multiple Myeloma 01/2023
1	Hematologic Diseases (Blood Diseases) 01/2023
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023
1	Febrile Neutropenia 12/2022
1	Neutropenia 12/2022
1	Invasive Fungal Infections 10/2022
1	Bronchiolitis Obliterans Syndrome 10/2022
1	Acute Promyelocytic Leukemia 01/2021
1	Inflammation (Inflammations) 01/2021
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2019
1	Fatigue 01/2019
1	Dysbiosis 10/2018
1	Insulin Resistance 10/2018
1	Respiratory Insufficiency (Respiratory Failure) 01/2018
1	Infections 01/2018
1	Sepsis (Septicemia) 01/2018
1	Hyperbilirubinemia 10/2017

Drug/Important Bio-Agent (IBA)

37	venetoclaxIBA 01/2024 - 10/2016
21	Azacitidine (5 Azacytidine)FDA Link 12/2023 - 04/2013
8	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2022 - 11/2010
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2011
5	enasidenibIBA 01/2021 - 10/2017
5	glasdegibIBA 10/2020 - 01/2018
4	Decitabine FDA Link 01/2021 - 01/2018
3	ivosidenibIBA 01/2021 - 01/2020
3	Amino Acids FDA Link 11/2020 - 11/2018
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2020 - 10/2017
3	Daunorubicin (Cerubidine)FDA LinkGeneric 11/2019 - 01/2018
3	Lenalidomide (CC 5013)FDA Link 01/2019 - 04/2013
2	Monoclonal AntibodiesIBA 01/2023 - 01/2021
2	EnzymesIBA 01/2021 - 03/2015
2	CytokinesIBA 01/2021 - 01/2016
2	fms-Like Tyrosine Kinase 3IBA 10/2020 - 10/2016
2	isocitric acid (isocitrate)IBA 04/2020 - 01/2019
2	midostaurinIBA 11/2019 - 12/2017
2	parthenolideIBA 11/2016 - 10/2016
2	Oxidoreductases (Dehydrogenase)IBA 03/2015 - 03/2014
2	Tyrosine Kinase InhibitorsIBA 03/2015 - 09/2014
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 03/2015 - 05/2013
2	AldehydesIBA 01/2015 - 03/2014
2	Phosphotransferases (Kinase)IBA 09/2014 - 05/2013
1	cobimetinibIBA 01/2024
1	CalciumIBA 10/2023
1	navitoclaxIBA 09/2023
1	brexucabtagene autoleucelIBA 01/2023
1	asciminibIBA 01/2023
1	magrolimabIBA 01/2023
1	recombinant-rywn asparaginase erwinia chrysanthemiIBA 01/2023
1	vorasidenibIBA 01/2023
1	RG7388IBA 01/2023
1	molibresibIBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 10/2022
1	atezolizumabIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Lipase (Acid Lipase)FDA Link 01/2021
1	DCLL9718SIBA 01/2021
1	C-Type Lectins (C-Type Lectin)IBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2020
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2020
1	Niacinamide (Nicotinamide)FDA LinkGeneric 11/2020
1	AnthracyclinesIBA 10/2020
1	RNA (Ribonucleic Acid)IBA 12/2019
1	Core Binding Factors (Core-Binding Factor)IBA 11/2019
1	Gemtuzumab (Mylotarg)FDA Link 11/2019
1	Arginine (L-Arginine)FDA Link 01/2019
1	Electron Transport Complex II (Succinate-Coenzyme Q Reductase)IBA 01/2019
1	Cysteine (L-Cysteine)FDA Link 01/2019
1	Serotonin (5 Hydroxytryptamine)IBA 10/2018
1	Glucose (Dextrose)FDA LinkGeneric 10/2018
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 12/2017
1	Interleukin-1 (Interleukin 1)IBA 01/2017

Therapy/Procedure

28	Therapeutics 01/2024 - 05/2010
24	Drug Therapy (Chemotherapy) 01/2024 - 05/2010
4	Induction Chemotherapy 12/2021 - 01/2018
2	Salvage Therapy 09/2023 - 01/2023
2	Transplantation 01/2023 - 10/2022
2	Hematopoietic Stem Cell Transplantation 01/2023 - 10/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023
1	Immunotherapy 01/2023
1	Blood Transfusion (Blood Transfusions) 01/2021
1	Stem Cell Transplantation 10/2020
1	Remission Induction 10/2020
1	Heterologous Transplantation (Xenotransplantation) 01/2019